New Ampyra(R) (dalfampridine) study data reported at ECTRIMS
Posted: Fri Oct 15, 2010 9:18 am
Responders to Ampyra Showed Clinically Significant and Meaningful Improvement in Walking Ability Based on Recent Consensus Expert Group Criteria.
Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Ampyra is an oral medication approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310